about
Clostridium difficile infection.Spectrum of Clostridium difficile infections: Particular clinical situations.Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infection.An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.Clinical significance of direct cytotoxicity and toxigenic culture in Clostridium difficile infection.Optimizing the diagnostic testing of Clostridium difficile infection.C. difficile PCR-ribotype 023 might go undetected when using ChromId C. difficile agar.New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay?Correction for Alcalá et al., Comparison of GenomEra C. difficile and Xpert C. difficile as Confirmatory Tests in a Multistep Algorithm for Diagnosis of Clostridium difficile Infection.Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting.Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study.Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience.Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samples.Comparison of GenomEra C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection.Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfrRifaximin-resistant Clostridium difficile strains isolated from symptomatic patients.Erratum for Marín et al., Clostridium difficile Isolates with High Linezolid MICs Harbor the Multiresistance Gene cfrUncommon aetiological agents of catheter-related bloodstream infections.Catheter-related bloodstream infections caused by Gram-negative bacteria.Characterization of swine isolates of Clostridium difficile in Spain: a potential source of epidemic multidrug resistant strains?Catheter-related bloodstream infection caused by Enterococcus spp.Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting - CORRIGENDUM.In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in SpainFecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and resultsIs it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?Susceptibility of uncommon Candida species to systemic antifungals by the EUCAST methodologyClostridioides difficile contamination in a clinical microbiology laboratory?Evaluation of Clostridium difficile Infection with PET/CT Imaging in a Mouse ModelFaecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules
P50
Q30234876-B63F2C51-A4A6-4A1C-92FC-3D533A2AB314Q38678231-51257921-B25D-47E9-9222-16FC9B256F12Q38770154-F00F3626-9B93-4BE5-938E-7213BBDC8FB7Q38787464-4517178E-6AA4-4713-B772-829ABE767F79Q38824479-F07749D3-EBDB-48E0-9519-DC82348F7B31Q38909959-85585893-6C92-489D-9689-D47C51DA3BB4Q40363633-768B4A47-7579-43F8-B78E-3D431739438EQ40424423-33906ECE-149B-4536-98FE-BF5098F5398AQ40599818-7FC7DB85-116A-4CB8-A874-BB2361B5F536Q40788336-82DF4EAA-2041-44EE-88F0-38AD372087A8Q40794461-104E141D-2526-4E67-9A81-877864D38AA1Q41190755-6232C262-5AD1-4848-8713-5E4B684EE970Q41294771-DDC4985F-43E7-4E95-B5E5-335520746405Q41331732-24F6D9B6-FC2D-48CA-8C77-411B94F57C1FQ41632561-545DCC0A-7783-4EA6-BAD9-1D0DCDD99546Q41665158-92BBA159-6C4C-4247-8D91-CE7F33354E2FQ41668894-53FED9B9-D2CC-443D-AC64-77F40C07932BQ41989948-728EC0A3-9D98-438C-93B1-C7EBFC24C414Q42101830-9CB0C1AF-8802-41E8-9510-EF7333B8FDC0Q42212710-8AEFE8CF-7B39-4A4F-8CE2-AE9B59E54E8AQ42242117-2A5D0BE3-B045-458A-A7BA-46A2C36A3728Q42259080-AC8E5719-E703-4910-90E8-B2D80EB5A275Q45775682-A68B6CEC-78FA-45BB-8C50-1D470E96CB9BQ50082624-A8839178-5041-478D-910A-72DDAEB5E92FQ54573520-631679FD-696F-496B-9C19-07269D17CC51Q58405145-FAB2D248-701C-424C-8D3A-FE40AAF18632Q59131641-936F0C15-5A69-41D7-A831-27BC93EA9FE9Q64105108-A56A7857-40B7-40EC-93D1-2A09B6AA7FFDQ91542591-5029B9FC-D299-4187-9A4F-201EFF7031C7Q91711584-833B788B-49BF-4606-869C-090D4E22A02AQ91977764-2D4129C6-F273-4F29-AA82-B262B3A0F9FDQ92297483-12BD8EC7-A5DF-4A98-B006-534709B89ED8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena Reigadas
@ast
Elena Reigadas
@en
Elena Reigadas
@es
Elena Reigadas
@nl
Elena Reigadas
@sl
type
label
Elena Reigadas
@ast
Elena Reigadas
@en
Elena Reigadas
@es
Elena Reigadas
@nl
Elena Reigadas
@sl
prefLabel
Elena Reigadas
@ast
Elena Reigadas
@en
Elena Reigadas
@es
Elena Reigadas
@nl
Elena Reigadas
@sl
P106
P21
P31
P496
0000-0003-0609-1305